Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02103608
Other study ID # DO105306A
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2013
Est. completion date December 2014

Study information

Verified date September 2016
Source Home Skinovations Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a clinical study to determine the efficacy and safety of the Glide, hair removal photo-depilation device, for removing facial hairs. During the first stage, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment.


Description:

Study efficacy assessment:

Comparison of hair counts before treatments to 4 and 12 weeks follow up visits.

Study safety assessment:

1. Reported errors and near errors using the device

2. Device malfunctions which relate to device safety

3. Device related adverse events

4. Non device related adverse events (secondary endpoint)


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date December 2014
Est. primary completion date July 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 60 Years
Eligibility Inclusion Criteria:

1. Presence of unwanted hairs on the face

2. Skin Type I to IV (Fitzpatrick)

3. Adults older than 21 years of age but not more than 60 years of age.

4. Must be either post-menopausal or surgically steri-lized, or using a medically acceptable form of birth control (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or absti-nence).

5. Informed consent agreement by the subject.

6. Willingness to follow the treatment schedule and post treatment care.

Exclusion Criteria:

1. Malignant or pre-malignant pigmented lesions in the area to be treated.

2. Scarring or infection of the area to be treated.

3. Known photosensitivity.

4. Pregnancy or lactating

5. Subjects with Diabetes (Type I or II).

6. Presence of a suntan in the area to be treated.

7. Use of medication known to induce photosensitivity.

8. Subject is on anticoagulative medication or throm-boembolic condition.

9. Subjects with a pacemaker or internal defibrillator.

10. Use of NSAIDS two weeks prior to, and two weeks following the treatment.

11. Subjects that use waxing or other methods of photo-epilation 3 months prior to treatment.

12. Subjects that have been exposed to strong sunlight or an artificial tanning machine during the past 4 weeks

13. Subjects wearing a tattoo or permanent makeup on the area to be treated

14. Subjects with dark brown or black spots, such as large freckles, birth marks, moles or warts on the area to be treated

15. Subjects with Eczema, psoriasis, lesions, open wounds or active infections, such as cold sores in the area to be treated

16. Subjects with history of keloidal scar formation

17. Subjects with history of herpes outbreaks in the area of treatment, unless you have consulted your physician and received preventative treatment before using GlideTM

18. Subjects with epilepsy

19. Subjects using incontinence device, insulin pump, other active devices [NB: Protocol excludes pace-makers and internal defibrillators.]

20. Subjects with a history of skin cancer or areas of po-tential skin malignancies

21. Subjects who have received radiation therapy or chemotherapy treatments within the past 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Glide
6 facial hair reduction treatments with the Glide device, two weeks apart.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Home Skinovations Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary 1. Comparison of Hair Counts Before Treatments to 4 and 12 Weeks Follow up Visits. Hair count is going to be preformed and base line and compare with the count at 4 weeks and 12 weeks. % of hair reducation is going to be calculated. 4 weeks and 12 weeks post treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT00495443 - Enhanced Safety Aesthetic Laser System N/A
Not yet recruiting NCT06003062 - Suppression of Upper Lip Hair Growth Using Novel Hemp Extract
Active, not recruiting NCT00145288 - Prospective Study of Patients With Hirsutism Phase 2/Phase 3
Completed NCT00152048 - Evaluation of Eflornithine on Facial and Forearm Skin Phase 4
Enrolling by invitation NCT01461694 - Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser Phase 2/Phase 3
Not yet recruiting NCT00441948 - Enhanced Safety Laser Hair Removal System N/A
Completed NCT03673995 - Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS N/A
Recruiting NCT04979377 - Prevalence of Hyperandrogenism in Type 1 Diabetes
Completed NCT02494297 - DUS on the Prescribing Indications for CPA/EE in 5 European Countries
Completed NCT00960310 - Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions Phase 1
Completed NCT02793557 - Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth Phase 1/Phase 2
Completed NCT01555190 - Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone N/A
Completed NCT01817894 - Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism Phase 4
Completed NCT00143052 - Bone Status and Insulin Resistance in Hirsutism N/A
Recruiting NCT01338519 - Database Study on Patients With PCOS N/A
Recruiting NCT04292587 - Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group
Completed NCT00959335 - Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions Phase 1
Not yet recruiting NCT00371930 - Photodynamic Therapy for Permanent Hair Removal Phase 1/Phase 2